Gilead Sciences has filed for approval of JAK1 inhibitor filgotinib in Japan. The submission moves Gilead a step closer to selling the Galapagos-partnered drug to rheumatoid arthritis patients in the country.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,